Novavax COVID-19 Vaccine

ApprovedVaccine

NNovavax

Novavax COVID-19 Vaccine is one of 40 biologic programs targeting COVID-19. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

COVID-19Active, not recruiting

InfluenzaActive, not recruiting

COVID-19Approved

Active, not recruiting

InfluenzaPhase 3

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Novavax COVID-19 Vaccine

NNovavax

Approved

1 2

Biaxin

AbbVie

Preclinical

2 3

Stivarga

Bayer

Preclinical

1 4

Singulair

AstraZeneca

Preclinical

1 5

Nitrostat

VViatris Specialty LLC

Preclinical

1 6

Achromycin V

WWyeth-Lederle Vaccines

Preclinical

—7

Biological Data

UUniversity Hospital, Bordeaux

Preclinical

3 8

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

1 9

Blood Taken

HHospices Civils de Lyon

Preclinical

1 10

Tpa

UUniversity of Florida

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Active, not recruiting

Influenza

NCT06291857

Clinical

Trials by Indication[1]

Influenza2 trials

A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine

Active, not recruiting·NNovavax·Phase 3·NCT06291857·9,320 enrolled

A Study to Evaluate the Immune Response and Safety of a Seasonal Virus-Like Particle Influenza Vaccine in Healthy Young Adults

Completed·NNovavax·Phase 2·NCT01561768·500 enrolled

COVID-191 trial

The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection

Completed·SSarang K. Yoon, DO, MOH·Phase 4·NCT06065176·1,188 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Novavax COVID-19 Vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Novavax COVID-19 Vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Novavax COVID-19 Vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novavax company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Approved[1]
Company: NNovavax

Novavax COVID-19 Vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Influenza2 trials

COVID-191 trial

References

Drug Info

Quick Facts

Related News